Vestmark Advisory Solutions Inc. Has $13.47 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Vestmark Advisory Solutions Inc. boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 143.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 81,230 shares of the company’s stock after buying an additional 47,895 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Johnson & Johnson were worth $13,471,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of JNJ. Highline Wealth Partners LLC lifted its stake in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the period. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at $47,000. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at $49,000. Harvest Fund Management Co. Ltd acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at $52,000. Finally, Capital A Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $50,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on JNJ. Guggenheim reissued a “neutral” rating and issued a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Barclays upped their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Finally, Leerink Partnrs cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $174.50.

Johnson & Johnson Price Performance

JNJ stock opened at $174.29 on Thursday. The stock has a market cap of $419.75 billion, a PE ratio of 18.64, a price-to-earnings-growth ratio of 2.20 and a beta of 0.41. The stock has a 50-day moving average price of $160.42 and a two-hundred day moving average price of $158.01. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $174.76.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. Johnson & Johnson’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter last year, the company earned $2.82 EPS. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.